TrialX provides cutting-edge information on new medical treatments and clinical trials in your area.
Meet Dory , your personalized virtual assistant to find clinical trials. Go head, ask her anything. x
All > Massachusetts Investigators

Matthew H. Kulke

Dana-Farber/Harvard Cancer Center at Dana ...


Boston, Massachusetts - 02115 (617-632-4001)

Dana-Farber Cancer Institute


Boston, Massachusetts - 02115
  • CLINICAL TRIALS 3
  • CONDITIONS5
  • INTERVENTIONS6
  • SINCE2007
Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced High-Risk Neuroendocrine Tumor

December 2007 - January 2012
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

March 2010 - November 2011
Safety and Efficacy of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

April 2008 - August 2011
Carcinoma

Neuroendocrine Tumors

Carcinoid Tumor

Adenoma, Islet Cell

Carcinoma, Neuroendocrine

Bevacizumab

Recombinant Interferon Alfa-2b

Octreotide Acetate

Amg 479

Octreotide

Pasireotide

Related Investigators

Massimo Loda, MD

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute

Suzanne Shusterman

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Childrens Hospital Boston, Dana-Farber Cancer Institute. Children's Hospital Boston

Patrick Y. Wen, MD

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Dana-Farber Cancer Institute Dana Farber / Brigham and Women's Cancer Center Dana-Farber Cancer Institute, Center for Neuro-Oncology Dana-Farber Cancer Instiute

Lewis B. Silverman, MD

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Dana-Farber Cancer Institute and Children's Hospital Dana Faber Cancer Institute, Children's Hospital, Dept. of Pediatric Oncology Children's Hospital Boston Dana-Farber Cancer Institute

Kay Kehoe, Coordinator

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute

Jennifer Brown, MD

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Dana-Farber Cancer Institute

Rachel A. Freedman

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute

Edwin P. Alyea, MD

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Dana-Farber Cancer Institute

F. Stephen Hodi, MD

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute Dana-Farber Cancer Institute Dana-Farber Cancer Center

Beth A. Overmoyer, MD, FACP

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute

©2012 Applied Informatics, Inc.
As Seen On:
  • New York Times
  • USA Today
  • bio-itworld logo